Immune Checkpoint Inhibitors for Esophageal Cancer: OAJBS Publishers
Immune
Checkpoint Inhibitors for Esophageal Cancer by Shun Yamamoto* in Open Access Journal of Biomedical Science
(OAJBS)
Esophageal
cancer (EC) is the seventh most common cancer, and patients with advanced EC
have a poor prognosis. Recently, nivolumab and pembrolizumab, two immune
checkpoint inhibitors (ICIs) that inhibit programmed cell death protein 1, have
begun to be used for the treatment of advanced esophageal squamous cell
carcinoma (ESCC). Based on the ATTRACTION-3 and KEYNOTE-181 trials, the use of
nivolumab and pembrolizumab (only in programmed cell death ligand 1-positive
cases) was approved for treatment by the US Federal Drug Administration for the
treatment of patients with advanced ESCC. In addition, the CheckMate-577 and
the KEYNOTE-590 trials have shown survival benefits for postoperative nivolumab
in patients with resectable EC and for first line pembrolizumab plus doublet
chemotherapy in patients with advanced EC, respectively. Many trials to
evaluate ICI-containing treatments are ongoing, and these new treatments are
expected to improve the clinical outcomes of patients with EC.
https://biomedscis.com/fulltext/immune-checkpoint-inhibitors-for-esophageal-cancer.ID.000267.php
To Know More About Open Access Journal of Biomedical Science Please Visit: Biomedscis
Are Click on: https://Biomedscis.Com/
Comments
Post a Comment